Icon

Aligos Therapeutics Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.13

-0.01 (-0.88)%

USD 0.05B

0.03M

USD 4.33(+283.48%)

USD 2.00 (+76.99%)

Icon

ALGS

Aligos Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 1.13
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.05B

USD 2.00 (+76.99%)

USD 1.13

Aligos Therapeutics Inc Stock Forecast

Show ratings and price targets of :
USD 4.33
(+283.48%)

Based on the Aligos Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Aligos Therapeutics Inc is USD 4.33 over the next 12 months. Aligos Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aligos Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Aligos Therapeutics Inc’s stock price was USD 1.13. Aligos Therapeutics Inc’s stock price has changed by +1.80% over the past week, -11.02% over the past month and -12.40% over the last year.

No recent analyst target price found for Aligos Therapeutics Inc
No recent average analyst rating found for Aligos Therapeutics Inc

Company Overview

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and...Read More

https://www.aligos.com

One Corporate Drive, South San Francisco, CA, United States, 94080

69

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Aligos Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.73 (-0.53%) USD84.99B 26.53 16.84

ETFs Containing ALGS

Symbol Name ALGS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About ALGS Stock

Based on ratings from 2 analysts Aligos Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.

Unfortunately we do not have enough data on ALGS's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for ALGS is USD 4.33 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 3.

Unfortunately we do not have enough data on ALGS's stock to indicate if its overvalued.

The last closing price of ALGS's stock was USD 1.13.

The most recent market capitalization for ALGS is USD 0.05B.

Based on targets from 2 analysts, the average taret price for ALGS is projected at USD 4.33 over the next 12 months. This means that ALGS's stock price may go up by +283.48% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...